Literature DB >> 26627832

Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.

Xiaoyan Gong1, Annette Ahner1, Ariel Roldan2, Gergely L Lukacs2, Patrick H Thibodeau3, Raymond A Frizzell4.   

Abstract

A newly identified pathway for selective degradation of the common mutant of the cystic fibrosis transmembrane conductance regulator (CFTR), F508del, is initiated by binding of the small heat shock protein, Hsp27. Hsp27 collaborates with Ubc9, the E2 enzyme for protein SUMOylation, to selectively degrade F508del CFTR via the SUMO-targeted ubiquitin E3 ligase, RNF4 (RING finger protein 4) (1). Here, we ask what properties of CFTR are sensed by the Hsp27-Ubc9 pathway by examining the ability of NBD1 (locus of the F508del mutation) to mimic the disposal of full-length (FL) CFTR. Similar to FL CFTR, F508del NBD1 expression was reduced 50-60% by Hsp27; it interacted preferentially with the mutant and was modified primarily by SUMO-2. Mutation of the consensus SUMOylation site, Lys(447), obviated Hsp27-mediated F508del NBD1 SUMOylation and degradation. As for FL CFTR and NBD1 in vivo, SUMO modification using purified components in vitro was greater for F508del NBD1 versus WT and for the SUMO-2 paralog. Several findings indicated that Hsp27-Ubc9 targets the SUMOylation of a transitional, non-native conformation of F508del NBD1: (a) its modification decreased as [ATP] increased, reflecting stabilization of the nucleotide-binding domain by ligand binding; (b) a temperature-induced increase in intrinsic fluorescence, which reflects formation of a transitional NBD1 conformation, was followed by its SUMO modification; and (c) introduction of solubilizing or revertant mutations to stabilize F508del NBD1 reduced its SUMO modification. These findings indicate that the Hsp27-Ubc9 pathway recognizes a non-native conformation of mutant NBD1, which leads to its SUMO-2 conjugation and degradation by the ubiquitin-proteasome system.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; Prot; SUMO; SUMOylation; chloride channel; cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR); post-translational modification (PTM); protein conformation; protein degradation

Mesh:

Substances:

Year:  2015        PMID: 26627832      PMCID: PMC4722474          DOI: 10.1074/jbc.M115.685628

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  The molecular chaperone alpha-crystallin is in kinetic competition with aggregation to stabilize a monomeric molten-globule form of alpha-lactalbumin.

Authors:  R A Lindner; T M Treweek; J A Carver
Journal:  Biochem J       Date:  2001-02-15       Impact factor: 3.857

2.  The deubiquitinating enzyme USP10 regulates the endocytic recycling of CFTR in airway epithelial cells.

Authors:  Jennifer M Bomberger; Roxanna L Barnaby; Bruce A Stanton
Journal:  Channels (Austin)       Date:  2010 May-Jun       Impact factor: 2.581

3.  The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation.

Authors:  G C Meacham; C Patterson; W Zhang; J M Younger; D M Cyr
Journal:  Nat Cell Biol       Date:  2001-01       Impact factor: 28.824

4.  Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants.

Authors:  Fei Sun; Ruilin Zhang; Xiaoyan Gong; Xuehui Geng; Peter F Drain; Raymond A Frizzell
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

5.  The small heat-shock chaperone protein, alpha-crystallin, does not recognize stable molten globule states of cytosolic proteins.

Authors:  T M Treweek; R A Lindner; M Mariani; J A Carver
Journal:  Biochim Biophys Acta       Date:  2000-08-31

6.  Physiology of epithelial chloride and fluid secretion.

Authors:  Raymond A Frizzell; John W Hanrahan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

7.  Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy.

Authors:  Oleg V Evgrafov; Irena Mersiyanova; Joy Irobi; Ludo Van Den Bosch; Ines Dierick; Conrad L Leung; Olga Schagina; Nathalie Verpoorten; Katrien Van Impe; Valeriy Fedotov; Elena Dadali; Michaela Auer-Grumbach; Christian Windpassinger; Klaus Wagner; Zoran Mitrovic; David Hilton-Jones; Kevin Talbot; Jean-Jacques Martin; Natalia Vasserman; Svetlana Tverskaya; Alexander Polyakov; Ronald K H Liem; Jan Gettemans; Wim Robberecht; Peter De Jonghe; Vincent Timmerman
Journal:  Nat Genet       Date:  2004-05-02       Impact factor: 38.330

8.  Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Authors:  Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

9.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

Authors:  Tsukasa Okiyoneda; Guido Veit; Johanna F Dekkers; Miklos Bagdany; Naoto Soya; Haijin Xu; Ariel Roldan; Alan S Verkman; Mark Kurth; Agnes Simon; Tamas Hegedus; Jeffrey M Beekman; Gergely L Lukacs
Journal:  Nat Chem Biol       Date:  2013-05-12       Impact factor: 15.040

Review 10.  Rescue of folding defects in ABC transporters using pharmacological chaperones.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

View more
  18 in total

Review 1.  The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation.

Authors:  G Michael Preston; Jeffrey L Brodsky
Journal:  Biochem J       Date:  2017-02-15       Impact factor: 3.857

Review 2.  Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications.

Authors:  Michelle L McClure; Stephen Barnes; Jeffrey L Brodsky; Eric J Sorscher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-29       Impact factor: 5.464

3.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

4.  HDAC inhibitors rescue multiple disease-causing CFTR variants.

Authors:  Frédéric Anglès; Darren M Hutt; William E Balch
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

Review 5.  From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking.

Authors:  Carlos M Farinha; Sara Canato
Journal:  Cell Mol Life Sci       Date:  2016-10-03       Impact factor: 9.261

6.  A topological switch in CFTR modulates channel activity and sensitivity to unfolding.

Authors:  Daniel Scholl; Maud Sigoillot; Marie Overtus; Rafael Colomer Martinez; Chloé Martens; Yiting Wang; Els Pardon; Toon Laeremans; Abel Garcia-Pino; Jan Steyaert; David N Sheppard; Jelle Hendrix; Cédric Govaerts
Journal:  Nat Chem Biol       Date:  2021-08-02       Impact factor: 15.040

7.  Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation.

Authors:  Darren M Hutt; Salvatore Loguercio; Daniela Martino Roth; Andrew I Su; William E Balch
Journal:  J Biol Chem       Date:  2018-07-13       Impact factor: 5.157

Review 8.  Post-translational modifications of transporters.

Authors:  Lindsay C Czuba; Kathleen M Hillgren; Peter W Swaan
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

9.  Management of tandem occlusions in patients who receive rtPA.

Authors:  Keaton S Smetana; Amanda Zakeri; Jaydevsinh Dolia; Allyson Huttinger; Casey C May; Patrick Youssef; Bradley A Gross; Shahid M Nimjee
Journal:  J Thromb Thrombolysis       Date:  2021-06-23       Impact factor: 2.300

Review 10.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.